UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,588	11/21/2003	Achim Ansmann	C 2586 COGG	3271
23657 COGNIS CORI	7590 03/06/200 PORATION	EXAMINER		
PATENT DEPA			KANTAMNENI, SHOBHA	
300 BROOKSIDE AVENUE AMBLER, PA 19002			ART UNIT	PAPER NUMBER
·			1617	
			MAIL DATE	DELIVERY MODE
			03/06/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/719,588	ANSMANN ET AL.	
Examiner	Art Unit	

	Shoona Kantannieni	1017	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>06 February 2008</u> FAILS TO PLACE THIS A	APPLICATION IN CONDITION FO	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appelor Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing	date of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth atter than SIX MONTHS from the mailing	date of the final rejection	n.
Examiner Note: If box 1 is checked, check either box (a) or (i MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	7).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply original controls.	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be t	iled within two month	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, be (a) ☐ They raise new issues that would require further cor 	nsideration and/or search (see NOT		cause
(b) They raise the issue of new matter (see NOTE below	· ·		
(c) ☐ They are not deemed to place the application in bett appeal; and/or			ne issues for
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):			
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).			_
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows: Claim(s) allowed: <u>NONE</u> . Claim(s) objected to: Claim(s) rejected: <u>1-5 and 13-17</u> .		be entered and an e	xplanation of
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ıl and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a).
10. 🔲 The affidavit or other evidence is entered. An explanation	n of the status of the claims after er	ntry is below or attach	ed.
REQUEST FOR RECONSIDERATION/OTHER			
 The request for reconsideration has been considered but <u>See page 2.</u> 		condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s).	PTO/SB/08) Paper No(s)		
13. Other:			
/SREENI PADMANABHAN/ Supervisory Patent Examiner, Art Unit 1617			
•			

Continuation of 11: Applicant's arguments have been considered, but not found persuasive. All the rejections made in the final office action are maintained.

112, first paragraph rejection:

Applicant argues that "The Examiner's attention is directed to page 3, lines 17-19, and page 4, lines 15-20, where the amounts of the compounds in the cosmetic preparations and pharmaceutical compositions are described. Therefore, no new matter is added." This argument is considered, but not found persuasive because page 4, lines 15-20, with the specific amounts refer only to cosmetic preparations and not to pharmaceutical preparations.

Rejection under 103(a):

Applicant's arguments have been considered, but not found persuasive.

As discussed in the final office action, it would have been obvious to a person of ordinary skill in the art at the time of the invention to the particular instant compound of formula (III) or (IV) in the prior art composition of Luisi because Luisi teaches that cycloalkanes which include bicyclohexyl compounds, cyclopentane are known to be useful as solvents in pharmaceutical preparation.

Therefore, one of ordinary skill in the art would have been reasonably expected that the instant particular compound of formula (III), or (IV), would have same or substantially similar usefulness as solvents in pharmaceutical preparation, based on the reasonable expectation that structurally similar species usually have similar properties. See, e.g., Dillon, 919 F.2d at 693, 696, 16 USPQ2d at 1901, 1904. See also Deuel, 51 F.3d at 1558, 34 USPQ2d at 1214, and if the claimed invention and the structurally similar prior art species share any useful property, that will generally be sufficient to motivate an artisan of ordinary skill to make the claimed species. In fact, similar properties may normally be presumed when compounds are very close in structure. Dillon, 919 F.2d at 693, 696, 16 USPQ2d at 1901, 1904, as noted in MPEP 2144. Further, one having ordinary skill in the art at the time the invention was made would have been motivated to determine the effective amounts of bicyclohexyl compounds employed in the compositions, since the optimization of effective amounts, is considered well in the competence level of an ordinary skilled artisan in cosmetic and pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See In re Boesch, 205 USPQ 215 (CCPA 1980).